{
    "clinical_study": {
        "@rank": "29958", 
        "arm_group": {
            "arm_group_label": "Targinact\u00ae (oxycodon/naloxon)"
        }, 
        "brief_summary": {
            "textblock": "This non-interventional, observational study evaluates the efficacy of Targinact with regard\n      to quality of life in daily clinical practice in Belgium compared to the previous analgesic\n      treatment."
        }, 
        "brief_title": "A Non-interventional, Observational Study for Quality of Life (Overall Health Assessment) in Patients With Chronic Severe Pain During Targinact\u00ae Treatment", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Severe Pain", 
        "detailed_description": {
            "textblock": "Patients are treated with Targinact\u00ae according to daily clinical practice during at least 12\n      weeks and are monitored during study 3 visits. Parameters assessed are overall health\n      assessment of the patient, pain relief, constipation, use of laxatives, use of analgesic\n      rescue medication, use of concomitant medication, quality of life and safety of Targinact\u00ae\n      treatment. These parameters, except for safety assessment, are compared between Targinact\u00ae\n      treatment and previous analgesic treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        Patients enrolled in the study  are patients who\n\n          -  are eligible for Targinact\u00ae treatment according to the Targinact\u00ae SPC AND\n\n          -  who have previously been treated with WHO step 1, 2 or 3 analgesics\n\n        Exclusion criteria are based on the Targinact\u00ae SPC."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Primary and Secondary care"
            }
        }, 
        "enrollment": {
            "#text": "1800", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01710917", 
            "org_study_id": "OXN9512"
        }, 
        "intervention": {
            "arm_group_label": "Targinact\u00ae (oxycodon/naloxon)", 
            "intervention_name": "Targinact\u00ae (oxycodon/naloxon)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Analgesics"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Chronic pain", 
            "Severe pain", 
            "Oxycodon", 
            "Naloxon", 
            "Opioid-induced constipation", 
            "Opioid", 
            "Quality of life", 
            "Laxative", 
            "Analgesic rescue medication"
        ], 
        "lastchanged_date": "November 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Brussels", 
                    "country": "Belgium"
                }, 
                "name": "University Hospital Brussels (UZ Brussel), Belgium"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_groups": "1", 
        "official_title": "The Efficacy of Targinact\u00ae Treatment With Respect to Quality of Life (Overall Health Assessment) in Chronic Severe Pain Patients Compared to Previous Analgesic Treatment: a Non-interventional, Observational Study.", 
        "overall_contact": {
            "email": "Info@contact-clinical-trials.com", 
            "last_name": "Maggie C Wilson"
        }, 
        "overall_contact_backup": {
            "email": "Info@contact-clinical-trials.com", 
            "last_name": "Jill Kiteley"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary parameter to assess the efficacy of Targinact\u00ae treatment with respect to the quality of life (overall health assessment/EQ-VAS) in patients with chronic severe pain compared to previous analgesic treatment is the absolute change in overall health score (0-100) attributed by patients during Targinact\u00ae treatment compared to previous analgesic treatment.\nDuring each visit, patients will be asked to score their overall health state between 0 (worst health state imaginable) and 100 (best health state imaginable). The absolute changes in overall health assessment from baseline at V2 and V3 will be used to compare health assessment during Targinact\u00ae treatment.", 
            "measure": "Assess the efficacy of Targinact\u00ae treatment", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01710917"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To assess pain (NRS) during Targinact\u00ae treatment compared to previous analgesic treatment (by physician)", 
                "measure": "\u2022 To assess pain (NRS) during Targinact\u00ae treatment compared to previous analgesic treatment (by physician)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "To assess constipation (BFI) during Targinact\u00ae treatment compared to previous analgesic treatment (by physician)", 
                "measure": "To assess constipation (BFI) during Targinact\u00ae treatment compared to previous analgesic treatment (by physician)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "To assess laxative use during Targinact\u00ae treatment compared to previous analgesic treatment (by physician)", 
                "measure": "To assess laxative use during Targinact\u00ae treatment compared to previous analgesic treatment (by physician)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "To assess the use of analgesic rescue medication during Targinact\u00ae treatment compared to previous analgesic treatment (by physician)", 
                "measure": "To assess the use of analgesic rescue medication during Targinact\u00ae treatment compared to previous analgesic treatment (by physician)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "To evaluate the quality of life (EQ-5D questionnaire) during Targinact\u00ae treatment compared to previous analgesic treatment (by patient)", 
                "measure": "To evaluate the quality of life (EQ-5D questionnaire) during Targinact\u00ae treatment compared to previous analgesic treatment (by patient)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Safety will be assessed by documentation of adverse events, collected via spontaneous reports and patient documentation.", 
                "measure": "To assess safety of Targinact\u00ae treatment (by physician)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Mundipharma CVA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mundipharma CVA", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}